Centric Compounding Recalled Injectable Glutathione Lots

The recall follows reports of severe adverse reactions linked to elevated endotoxin levels in the injectable products.

Updated on Sept. 18, 2026 in COVID-19

Bold flat-color editorial illustration of a single glass vial, evoking the medical recall of injectable glutathione products. — Centric Compounding has issued a nationwide recall for six lots of injectable glutathione after reports of severe adverse reactions including fever and chest pain. AI Illustration. Upload story photo >

Live Poll

Do you trust the safety of injectable treatments offered at non-traditional wellness clinics?

Centric Compounding has recalled six lots of injectable glutathione products after reports of patients falling ill. At least 30 individuals experienced adverse symptoms, including fever and chest pain, following the use of the compounded vials.

Why it matters

The recall was initiated because the products contained elevated endotoxin levels, which can lead to severe medical complications or death. The FDA has previously warned that there are no approved injectable glutathione products and that dietary-grade supplements should not be used in injectables.

The recall encompasses six lots of 200 mg/ML Glutathione, Meyer's Cocktail, and Tri-Immune Boost, which were compounded using dietary supplement-grade ingredients. At least three patients required hospitalization, including one requiring intensive care.

The players

Centric Compounding

This compounding pharmacy creates medications in forms not typically offered by commercial manufacturers.

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products.

CDC

The Centers for Disease Control and Prevention is the national public health agency that leads investigations into outbreaks and illness clusters.

Medisca, Inc.

This company acts as a supplier of pharmaceutical-grade chemicals and ingredients for use in compounding pharmacies.

The details

The pharmacy mixed these products using glutathione sourced from Medisca, Inc., which was intended for dietary supplement use rather than clinical injections. Patients reported adverse symptoms such as fever, chills, chest pain, and nausea after receiving the treatments.

Texas health authorities notified the CDC of illness reports in July 2026.
The FDA issued an alert regarding glutathione compounding in August 2026.
The CDC recorded over 25 illness reports across at least four states as of September 11, 2026.
Centric Compounding issued a recall for six lots of products on September 18, 2026.

The Big Picture

This recall highlights the persistent risks associated with the FDA's regulatory framework for compounding pharmacies. It follows a pattern of heightened scrutiny regarding the use of non-approved ingredients in injectable medications that bypass standard commercial drug safety testing.

Patients who have recently received compounded glutathione injections should monitor themselves for symptoms like fever, nausea, or chest pain and seek immediate medical attention if they appear. Those who have purchased these products should discontinue use and consult their healthcare provider.

The takeaway

Patients should exercise extreme caution with any injectable treatments that are not FDA-approved, as compounding pharmacies are not subject to the same oversight as commercial drug manufacturers. Always verify the source and intended use of any ingredients included in compounded medical therapies.